FDA AdCom recommends GSK’s anti-BCMA drug for approval 12-0 despite searing in-house review — does it matter?
The FDA may have ripped GlaxoSmithKline for the safety of its anti-BCMA drug, but that didn’t stop an advisory committee from voting 12-0 to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
